0

Journal Articles

in Psychopharmacology
 21-40 of 92 Articles
JAMA | 
Original Contribution |  January 02, 2013
Selective Serotonin Reuptake Inhibitors During Pregnancy and Risk of Stillbirth and Infant Mortality
Olof Stephansson, MD, PhD; Helle Kieler, MD, PhD; Bengt Haglund, PhD; et al.
JAMA. 2013;309(1):48-54. doi:10.1001/jama.2012.153812.
INCLUDES: , Supplemental Content
JAMA Psychiatry | 
Original Article |  January 01, 2013
A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression:  The Role of Baseline Inflammatory Biomarkers
Charles L. Raison, MD; Robin E. Rutherford, MD; Bobbi J. Woolwine, MSW; et al.
JAMA Psychiatry. 2013;70(1):31-41. doi:10.1001/2013.jamapsychiatry.4.
INCLUDES: , Supplemental Content
JAMA | 
Medical News and Perspectives |  December 19, 2012 FREE
A Trip on “Bath Salts” Is Cheaper Than Meth or Cocaine But Much More Dangerous
Anita Slomski
JAMA. 2012;308(23):2445-2447. doi:10.1001/jama.2012.34423.
JAMA Internal Medicine | 
Research Letters |  December 10, 2012
Management of Substance Use Disorders in Ambulatory Care in the United States, 2001-2009
Joseph W. Frank, MD; John Z. Ayanian, MD, MPP; Jeffrey A. Linder, MD, MPH
Arch Intern Med. 2012;172(22):1759-1760. doi:10.1001/archinternmed.2012.4504.
JAMA Psychiatry | 
Original Article |  December 01, 2012
National Trends in the Office-Based Treatment of Children, Adolescents, and Adults With Antipsychotics
Mark Olfson, MD, MPH; Carlos Blanco, MD, PhD; Shang-Min Liu, MS; et al.
Arch Gen Psychiatry. 2012;69(12):1247-1256. doi:10.1001/archgenpsychiatry.2012.647.
INCLUDES: , Supplemental Content
JAMA Psychiatry | 
Original Article |  December 01, 2012
Improvement of Brain Reward Abnormalities by Antipsychotic Monotherapy in Schizophrenia
Mette Odegaard Nielsen, MD, PhD; Egill Rostrup, MD, DMSc; Sanne Wulff, MD; et al.
Arch Gen Psychiatry. 2012;69(12):1195-1204. doi:10.1001/archgenpsychiatry.2012.847.
INCLUDES: , Supplemental Content
JAMA Psychiatry | 
Original Article |  December 01, 2012
Neural Correlates of Weight Gain With Olanzapine
Jose Mathews, MD; John W. Newcomer, MD; Jennifer R. Mathews, PhD; et al.
Arch Gen Psychiatry. 2012;69(12):1226-1237. doi:10.1001/archgenpsychiatry.2012.934.
INCLUDES: , Supplemental Content
JAMA | 
Capitol Health Call |  November 14, 2012
Overprescribing Antipsychotics
Mike Mitka, MSJ
JAMA. 2012;308(18):1849. doi:10.1001/jama.2012.33462.
JAMA Ophthalmology | 
Ophthalmic Images |  November 01, 2012
Chlorpromazine-Induced Corneal Toxicity
Victor Koh, MBBS; Wei-Boon Khor, MRCS(Ed); Li Lim, FRCS(Ed)
Arch Ophthalmol. 2012;130(11):1409. doi:10.1001/archophthalmol.2012.475.
JAMA Internal Medicine | 
Editor's Correspondence |  October 22, 2012
Generic Competition in a Flawed System: Pill Them, Bill Them
Alain Braillon, MD, PhD
Arch Intern Med. 2012;172(19):1522-1523. doi:10.1001/archinternmed.2012.4389.
JAMA Ophthalmology | 
Research Letters |  October 01, 2012
Systemic Uptake of Chlorpromazine After Delivery via Retrobulbar Injection
Ruben Kuruvilla, MD; Priya D. Sahu, MD; Murray A. Meltzer, MD
Arch Ophthalmol. 2012;130(10):1348-1349. doi:10.1001/archophthalmol.2012.662.
JAMA | 
Health Agencies Update |  September 26, 2012
Off-label Atypical Antipsychotics
Bridget M. Kuehn
JAMA. 2012;308(12):1198. doi:10.1001/2012.jama.12018.
JAMA | 
Users' Guides to the Medical Literature |  September 26, 2012
How to Use an Article Reporting a Multiple Treatment Comparison Meta-analysis
Edward J. Mills, PhD, MSc; John P. A. Ioannidis, MD, DSc; Kristian Thorlund, PhD, MSc; et al.
JAMA. 2012;308(12):1246-1253. doi:10.1001/2012.jama.11228.
INCLUDES: , Supplemental Content
JAMA Psychiatry | 
Original Article |  September 01, 2012
Common and Unique Therapeutic Mechanisms of Stimulant and Nonstimulant Treatments for Attention-Deficit/Hyperactivity Disorder
Kurt P. Schulz, PhD; Jin Fan, PhD; Anne-Claude V. Bédard, PhD; et al.
Arch Gen Psychiatry. 2012;69(9):952-961. doi:10.1001/archgenpsychiatry.2011.2053.
INCLUDES: , Supplemental Content
JAMA Psychiatry | 
Original Article |  September 01, 2012
Randomized Trial of Long-Acting Sustained-Release Naltrexone Implant vs Oral Naltrexone or Placebo for Preventing Relapse to Opioid Dependence
Evgeny Krupitsky, MD, PhD, DMedSci; Edwin Zvartau, MD, PhD, DMedSci; Elena Blokhina, MD, PhD; et al.
Arch Gen Psychiatry. 2012;69(9):973-981. doi:10.1001/archgenpsychiatry.2012.1a.
JAMA Pediatrics | 
Advice for Patients |  September 01, 2012 FREE
Adolescent Opioid Abuse
Megan A. Moreno, MD, MSEd, MPH; Fred Furtner; Frederick P. Rivara, MD, MPH
Arch Pediatr Adolesc Med. 2012;166(9):880. doi:10.1001/archpediatrics.2012.1765.
JAMA Psychiatry | 
Original Article |  September 01, 2012
Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug–Induced Weight Gain
Anil K. Malhotra, MD; Christoph U. Correll, MD; Nabilah I. Chowdhury, BSc; et al.
Arch Gen Psychiatry. 2012;69(9):904-912. doi:10.1001/archgenpsychiatry.2012.191.
INCLUDES: , Supplemental Content
JAMA Pediatrics | 
Editorial |  September 01, 2012
Adolescent Abuse of Pharmaceutical Opioids Raises Questions About Prescribing and Prevention
Caleb J. Banta-Green, PhD, MPH, MSW
Arch Pediatr Adolesc Med. 2012;166(9):865-866. doi:10.1001/archpediatrics.2012.590.
JAMA Pediatrics | 
Article |  September 01, 2012
Medical and Nonmedical Use of Prescription Opioids Among High School Seniors in the United States
Sean Esteban McCabe, PhD; Brady T. West, PhD; Christian J. Teter, PharmD; et al.
Arch Pediatr Adolesc Med. 2012;166(9):797-802. doi:10.1001/archpediatrics.2012.85.
JAMA Internal Medicine | 
Research Letters |  August 13, 2012
Prescription Drug Abuse and DEA-Sanctioned Drug Take-Back Events: Characteristics and Outcomes in Rural Appalachia
Jeffrey A. Gray, PharmD; Nicholas E. Hagemeier, PharmD, PhD
Arch Intern Med. 2012;172(15):1186-1187. doi:10.1001/archinternmed.2012.2374.

Sign In

Register for a FREE personal account

and access these and other features:

Register Now

Want to Subscribe?

Learn More about subscription options.

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

From The JAMA Network
JAMA Psychiatry
Original Article  |  March 27, 2013
Effects of Varenicline and Bupropion Sustained-Release Use Plus Intensive Smoking Cessation Counseling on Prolonged Abstinence From Smoking and on Depression, Negative Affect, and Other Symptoms of Nicotine Withdrawal
Paul M. Cinciripini, PhD; Jason D. Robinson, PhD; Maher Karam-Hage, MD; et al.
JAMA Internal Medicine
Original Investigation  |  April 29, 2013
Perioperative Use of Selective Serotonin Reuptake Inhibitors and Risks for Adverse Outcomes of Surgery
Andrew D. Auerbach, MD, MPH; Eric Vittinghoff, PhD; Judith Maselli, MSPH; et al.
JAMA Internal Medicine
Invited Commentary  |  April 29, 2013
Selective Serotonin Reuptake Inhibitors and Surgery: To Hold or Not to Hold, That Is the Question:  Comment on “Perioperative Use of Selective Serotonin Reuptake Inhibitors and Risks for Adverse Outcomes of Surgery”
Marko Mrkobrada, MD, FRCPC; Daniel G. Hackam, MD, PhD, FRCPC
JAMA Internal Medicine
Review Article  |  March 4, 2013
Pharmacologic Therapy for Primary Restless Legs Syndrome:  A Systematic Review and Meta-analysis
Timothy J. Wilt, MD, MPH; Roderick MacDonald, MS; Jeannine Ouellette; et al.
© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems